ccRCC | Image by Ashling Wahner
& MJH Life Sciences Using AI
Adjuvant pembrolizumab (Keytruda) demonstrated prolonged disease-free survival (DFS) and overall survival (OS) compared with placebo in patients with clear cell renal cell carcinoma (ccRCC), according to a landmark 5-year analysis from the phase 3 KEYNOTE-564 trial (NCT03142334) presented at the 2025 ASCO Annual Meeting.
At the 5-year analysis, the median DFS was not reached nor where either ends of the 95% confidence interval (CI) for those receiving pembrolizumab compared with 68.3 months for those in the placebo group (HR, 0.71; 95% CI, 0.59-0.86). The 72-month OS rate was 86.1% in the pembrolizumab arm compared with 79.4% in the placebo group. The median OS was not yet reached in either arm (HR, 0.66; 95% CI, 0.48-0.90).
“Pembrolizumab is the only adjuvant…